BMY
Bristol-Myers Squibb Company
October 12, 2026 · pre-market
- Rarity
- 1.59
- Peak move
- +5.95%
- Float cap
- $120.0B
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines for serious diseases. Its therapies target oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, government agencies, and patients.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 0 from SEC or newswire · 2 timed with the move- Timed with the move
clinical_readoutBristol Myers Squibb, through its RayzeBio unit, reported that the pivotal Phase 3 ACTION-1 trial of RYZ101 (225Ac-DOTATATE) met its primary endpoint with a statistically significant improvement in progression-free survival versus investigator's choice of standard of care in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors progressing after 177Lu-based therapy.
- Timed with the move
clinical_readoutBristol Myers Squibb said its pivotal Phase 3 ALOFT-IPF trial of admilparant in about 1,255 adults with idiopathic pulmonary fibrosis met its primary endpoint, with the 60 mg twice-daily dose showing a statistically significant improvement in absolute change in forced vital capacity at Week 52 versus placebo, while the 120 mg dose was not statistically significant.
analyst_ratingBank of America lowered its price target on Bristol Myers Squibb to $66.00 on October 9, 2026.
clinical_readoutBristol Myers Squibb said the Phase 3 EXCALIBER-RRMM trial of Zenbexus (iberdomide) plus dexamethasone and daratumumab met its primary endpoint in relapsed or refractory multiple myeloma, with median progression-free survival of 42 months versus 20 months for standard of care, a 51% reduction in risk of progression or death at 23 months' median follow-up.
analyst_ratingCantor Fitzgerald lowered its price target on Bristol Myers Squibb to $53.00 on October 8, 2026, maintaining a Neutral rating.
analyst_ratingRothschild & Co Redburn raised its price target on Bristol Myers Squibb to $53.00 on October 8, 2026.
analyst_ratingMorgan Stanley raised its price target on Bristol Myers Squibb to $41 from $40 while reiterating an Underweight rating.